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Abstract
Myasthenia gravis (MG) is an acquired autoimmune disorder causing skeletal muscle fatigue and
weakness. This is a report of one woman and her daughter presenting with myasthenia and gravis and
Grave’s disease. It highlights possible hereditary component of this condition which has not been
commonly reported in our setting.
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Résumé
Les gravis de Myasthenia (magnésium) est un désordre autoimmun acquis causant la fatigue et la
faiblesse de muscle squelettique. C'est un rapport d'une femme et de sa fille présent avec le
myasthenia et les gravis et la maladie de la tombe. Il accentue le composant héréditaire possible de
cette condition qui n'a pas été généralement rapportée dans notre arrangement.
Mots clés: Gravis de Myasthenia, la maladie thyroïde
Introduction
Myasthenia gravis (MG) is an autoimmune disease
characterized by impaired neuromuscular
transmission due to circulating antiacetylcholine
receptor auto antibodies (AchRAB).
1
The frequent
association of MG with thymic disease, such as
follicular hyperplasia and thymoma, suggests that the
thymus plays a role in its pathogenesis.
1-3
The clinical
expression of MG varies, ranging from a mild
localized disease such as ocular myasthenia gravis
(OMG) to a severe generalized disease.
4
Patients with MG may have evidence of coexisting
autoimmune thyroid disease (AITD)
5-8
as well as other
autoimmune disorder like type 1 diabetes, primary
hypogonadism, pernicious anemia, and adrenal
insufficiency. Collectively referred to as the
polyglandular syndrome (PGA).
Epidemiological studies showed that AITD occur
in approximately 5%-10% of MG patients.
9,10
Graves’
disease (GD) is the commonest AITD associated with
MG.
9,10
Graves’ disease and MG are more common in
females. A higher frequency of thyroid antibodies has
been observed in OMG compared to generalized
myasthenia gravis (GMG).
11
GD has been found to
coexist with OMG in 41.0% & GMG in 28.5% of a total
of 129 cases of myasthenia gravis studied.
11
The pattern of inheritance is unknown but high
frequency of human leukocyte antigen (HLA) B8 and
DR 3 has been reported in both disorders.
12-14
This
report highlights possible hereditary component of
this condition in our setting.
Case 1
A 46-year- old woman presented in 2000 with
excessive sweatiness, polyphagia, and occasional
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palpitation. At the age of 18 years she had diplopia,
ptosis and blurred vision. A diagnosis of MG was
made and subsequently she had thymectomy.
Physical examination revealed
hyperpigmentation, a warm, moist palm with
tremulous hands, and a firm diffusely enlarged goiter.
There was lid lag, lid retraction and exopthalmos. A
diagnosis of Graves’ disease was made and confirmed
by high levels of thyrotrophin, thyroxin and very low
thyroid stimulating hormone levels (Table 1). Serum
thyroid microsomal antibodies.
She was initially treated with azathioprine 25mg 3
times daily and prednisone 2.5mg 3 times daily. Six
months after her 2nd childbirth, treatment was
changed to pyridostigmine 30-60mg 3 times daily and
prednisone 10mg 3 times. Treatment for Grave’s
disease was with metimazole 15mg 3 times daily. She
has two daughters; one was diagnosed to have
myasthenia gravis and Graves’ disease at the age of
15yearrs and is being treated.
Case 2
A 24-year-old first daughter of case 1 was diagnosed
to have myasthenia gravis at the age of 15 years
when she presented with weakness, ptosis and
diplopia. She was commenced on treatment with
marked improvement, but developed intolerance to
heat, excessive eating, warm moist palms,
inattention in class and proptosis after 5 years. She
attained Menarche at eleven years of age with
regular menstrual flow.
Physical examination showed lid lag, lid
retraction, and exophthalmos in addition to a diffuse
goiter. A diagnosis of Graves’ disease was made and
confirmed by high levels of thyrotrophin, thyroxin
and low thyroid stimulating hormone (Table 1).
Serum thyroid microsomal antibodies was high. She
was placed on methimazole 10mg 3 times daily and
pyridostigmine 30mg 3 times daily. She has remained
well at follow up. Her only sister is apparently well
and thyroid antibody negative.
Table 1. Result of thyroid function and thyroid antibodies in the two patients
Tests Normal values Case 1 Case 2
T3 0.2-2.3ug/ul 4.2ug/ul 3.4ug/ul
T4 38-98ng/ul 160ng/ul 155ng/ul
TSH 1.0-5.2miu/l 0.74miu/l 0.86miu/l
STA Negative at 1:600 dilutions Negative at 1:600 dilutions
STMA Positive at1:6400 dilutions Positive at 1:6400 dilutions
T3: thyrotropin; T4:Thyroxin; TSH: thyroid stimulating hormone; STA: serum thyroglobulin antibodies; STMA: serum thyroid microsomal
antibodies
Discussion
Myasthenia gravis is an autoimmune neuromuscular
disorder often associated with thymic disease.
1-3
The
coexistence of other autoimmune diseases in MG is
well recognized,
6,7
including the association with
AITD.
6-8
However, the influence of AITD on the clinical
expression of MG has not been defined. Whether
AITD is more frequently association with OMG (as in
this cases) or GMG has not been evaluated and
whether the clinical expression of MG with coexistent
AITD is related to thyroid disease per se or to its
autoimmune component remains to be clarified.
In the present report clinical presentation of MG
associated with AITD was characterized by
neuromuscular involvement restricted to eye
muscles. Garlepp et al
5
reported increased
association between OMG and thyroid immunity and
greater frequency of thyroid antibodies in OMG than
GMG. Marino et al demonstrated that Graves’
disease patients with clinical evidence of
ophthalmopathy had a higher frequency of ocular






demonstrated milder clinical expression of MG in
patients with associated AITD than in those without
thyroid auto immunity.
The reason for the association of AITD with ocular
MG is unknown, but several hypotheses have been




immunological cross-reactivity against epitopes or
autoantigen shared by the thyroid and the eye
muscles might be the basis for this association.
17,18
Several experimental data suggest that the thyroid
antigens are presents in ocular tissues. Circulating
autoantibodies directed to eye muscles components
have been identified in GD with MG.
19,20
Explanation
for the higher frequency of OMG in AITD could be
that these disorders have a common genetic
background.
11
Also a high frequency of human-
leukocyte antigen B8 and DR3 has been reported in
both disorders.
11
The present report is a reminder that the clinical
features of autoimmune diseases can overlap. The
presence of one autoimmune disease should prompt
a search for other autoimmune diseases. It is
desirable that family members are screened to
exclude autoimmune disease.
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